Suppliers
Contact Us
GENTAUR Europe BVBA Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45 Fax 0032 16 50 90 45 This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. |
GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GmbH Marienbongard 20
52062 Aachen Deutschland
Tel (+49) 0241 56 00 99 68
Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531
Fax 020 8445 9411
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893
Fax 0497-517897
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Spain
Tel 0911876558
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Phone/Fax:
(408) 780-0908
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENPRICE Inc. invoicing/ accounting:
6017 Snell Ave, Suite 357
San Jose, CA. 96123
Serbia, Macedonia,
Montenegro, Croatia:
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Romania
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Greece
Tel 00302111768494
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
Other countries
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Ceská republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Magyarország Budapest +3619980547
OMNIA PRIMA automated system for extracting DNA and RNA
Description:
- Prima is an automated system for extracting DNA and RNA from blood, saliva or other biological fluid samples, solid tissues and plant samples. This workstation is based on magnetic bead technology and it is able to process up to 24 samples at a time in less than 100 minutes.
It is possible to use one of the recommended and validated extraction kits, whose automatic protocol is already available, or to test and employ other magnetic bead-based kits or specific protocols, counting on customized management for each lab.
- Prima has a high throughput capacity and allows extraction of highly-pure DNA or RNA, various downstream applications can be run on this platform, such as PCR, real-time PCR, sequencing libraries, microarray, enzymatic analysis.
Moreover, as all OMNIA workstations, Prima is very flexible so that it can be used for plate preparation and automatic pipetting to perform many protocols that can be quickly programmed.
Main features
- Easy and fast extraction from up to 24 blood, saliva or other biological fluid samples, tissues and plant samples without wasting of reagents or consumables
- Use of several validated commercial kits or test of specific kits
- High purity of extracted nucleic acid (A260/280 ratio DNA: 1.7-1.9, RNA: 1.9-2.1)
- High performance in downstream applications such as PCR and qPCR
- Decontamination through UV light
- Workstation suitable for other autosampling and liquid handling protocols
- User-friendly software with wireless remote control
Manufacturer: MASMEC
Discovery of a new intestinal virus
Scientists have discovered a previously unknown virus that lives in the human gut, according to a study published in Nature Communications.
An international team of scientists discovered the virus in CrAssphage genetic material from samples of intestine. Scientists believe the virus can affect the behavior of some of the most common bacteria in the intestinal flora.
Experts explain that these types of viruses called bacteriophages play an important role in chronic diseases. Leading a team from the State University at San Diego, USA, "clears" the genetic information that is stored in three large international databases.
They fall on the portion of the DNA to be detected in more than half of all the samples. Further analysis found that the virus has not been detected so far.
Scientists explain that it has a genetic fingerprint of the bacteriophage - type virus, which is known to infect the bacteria. He can control the behavior of bacteria that affect - in some cases makes it easier to live in the environment in which they are located, and may make the bacteria more powerful.
Scientists are trying to grow the virus in the laboratory. Explain that the next step will be to establish exactly the way in which the virus affects intestinal bacteria.
Gene mutation increases 10 times the risk of diabetes
Recently identified gene mutation increases the risk of developing type 2 diabetes tenfold. It was found in the DNA of the population of Greenland.
The study by scientists from Copenhagen gives a new perspective on innate predisposition and the real danger of diabetes.
Of course, the presence of the mutation TBC1D4, is not confined only within the largest island on the planet. It has already detected among many Europeans suffering from diabetes.
Its "arms" consists in the development of insulin resistance in muscle.
The discovery allows for harder prevention of diseases and the development of new techniques for treatment.
"We know that each of us has his heredity, which, unfortunately, when diabetes is critical. It is not enough to become diabetics. We do not inherit the disease, and the tendency of its manifestation.
Our meeting with a number of external factors such as viruses, chemicals, and other stressful situations may trigger a series of autoimmune processes in our body that damage and destroy cells of the pancreas that produce the hormone insulin, "comment the investigators.
They point out that diabetes is not a disease, as it causes many damages to the human body.
"We can not change our heredity, but we can change our lifestyle.
If you take care of your health in time through healthy eating and daily physical activity we can gain skills for coping with stress alone can reduce the likelihood of falling ill from diabetes, "concluded the report by researchers from Copenhagen.
Gene editing treat rare liver disease
Using a new system of genetic editing based on bacterial proteins by researchers from MIT cured rare liver disease caused by a single genetic mutation.
The findings described in the edition of Nature Biotechnology, provide the first evidence that the technique of editing of a gene known as CRISPR, can reverse disease symptoms.
CRISPR, which offers an easy way to crop the mutated DNA and replacement with the correct sequence has the potential to treat many genetic diseases, according to the research team.
Recently developed CRISPR system relies on cellular mechanism that bacteria use to protect themselves from viral infection.
Researchers have copied this cell system for the creation of gene-editing complexes, including DNA.
They are cut enzyme called Cas9, bound to the RNA strand, which can be programmed to bind to a specific genomic sequence.
Meanwhile, researchers deliver DNA template strand.
When repairing cell damage resulting from Cas9, scientists introduced the template DNA in the genome.
Scientists predict that this type of revision of the genome one day could help in the treatment of diseases such as hemophilia, Huntington's disease, and the like, caused by a single mutation.
There are other systems developed on the basis of genetic editing of DNA enzymes known as nucleases, but these complexes can be expensive and difficult to assemble.
In contrast, CRISPR is very easy to configure and customize equipment.
Lipofector EXT, Lipofector Q and Plusfector
For broad cell lines, up to 100% transfection efficiency
Description
• High transfection efficiency in a broad spectrum of commonly transfected cell lines
• High performance for the delivery of plasmid DNA, siRNA, antisense oligo and miRNA
• Highest quality assured : endotoxin & sterility tests are passed.
Transfection Efficiency
• Cell Line : COS7
• DNA : pcDNA-GFP 0.4 ug/well
• Cell Line : 293A
• DNA : mCherry 20ug/Well
• Cell Line : MCF-7
• DNA : pcDNA-GFP 0.3ug/Well
Listed products
• Lipofector-Q
- Liposomal transfection reagent
• Plusfector
- Reagent enhances transfection mediated by cationic lipids
• Lipofector-EXT
- Kits of Lipofector Q and Plusfector
Key Features of Lipofector and Plusfector
• Excellent transfection efficiency
- Achieves high efficiency and expression results for plasmid or RNAi
transfections
• Wide range of successfully transfected cell lines
- Works effectively with many cell types (adherent or suspension)
• Cost effective products
Ordering information
Product name | Cat.No. |
Product size |
Price |
Lipofector-Q | AB-LF-Q001 | 1ml | 322€ |
AB-LF-Q004 | 4ml | 902€ | |
Lipofector -EXT | AB-LF-EXT101 | 1ml | 396€ |
AB-LF-EXT104 | 4ml | 1162€ | |
Plusfector | AB-PF-0001 | 1ml | 229€ |
More: Lipofectors
Lipofector 2000 and Lipofector EZ
For broad cell lines, lipofector-2000 or Lipofector-EZ Reagent delivers
DNA or siRNA with excellent transfection performance.
Description
- - High transfection efficiency in a broad spectrum of commonly transfected cell lines
- High performance for the delivery of plasmid DNA, siRNA, antisense oligo and miRNA
- Highest quality assured : endotoxin & sterility tests are passed.
Transfection Efficiency
- Cell Line : 293T
- DNA : pcDNA-GFP 0.2 ug/well
- Cell Line : MCF7
- DNA : pcDNA-GFP 0.4 ug/well
- Cell Line : 293T
- RNA : 5'cap-Fluc RNA reporter 0.2 ug/well
Key Features of Lipofector 2000 and Lipofector EZ
- • Excellent transfection efficiency
- Achieves high efficiency and expression results for plasmid or RNAi
transfections
• Wide range of successfully transfected cell lines
- Works effectively with many cell types (adherent or suspension)
• Convenient protocol
- Highly efficient transfection ratio in serum containing medium.
• Cost effective products
Product name | Cat.No. | Product size | Price |
Lipofector-2000 | AB-LF-2001 | 0.75 ml | 316€ |
AB-LF-2002 | 1.5 ml | 461€ | |
Lipofector-EZ | AB-LF-EZ075 | 0.75 ml | 318€ |
AB-LF-EZ100 | 1.0 ml | 364€ | |
AB-LF-EZ150 | 1.5 ml | 463€ | |
Lipofector-2000/EZ Combo | AB-LF-C075 | 0.75 ml + 0.75 ml | 469€ |
More: Lipofectors
JETSTAR 2.0 Maxi
Description:
JETSTAR is a new and unique anion exchange resin
developed by Gentaur. This new resin is supplied in disposable
columns (Mini, Midi and Maxi columns) , which are used
under gravity flow conditions without further instrumentation.
The JETSTAR Plasmid Kits were designed by combining
JETSTAR Columns with a modified alkaline/SDS lysis proce-
dure for the preparation of plasmid DNA. Gentaur´s product
is the ideal tool to achieve ultrapure plasmid DNA within 45
Procedure :The procedure employs a modified alkaline/SDS method to prepare the cleared lysate. After neutral-ization, the lysate is applied onto a JETSTAR Column (Mini, Midi or Maxi) and the plasmid DNA is bound to the anion exchange resin . Washing the resin removes RNA and all other impurities. Finally the purified plasmid DNA is eluted from the column and concentrated by an alcohol precipitation.
Plasmid yields :Yields of up to 20 µg (Mini), 100 µg (Midi) and 500 µg (Maxi) of plasmid DNA can be expected using the JETSTAR columns. All types and sizes of plasmid DNA can be prepared, but yields depend very much on the plasmid copy numbers (low/medium/high), the type f plasmid, the bacterial strain and the volume of bacterial culture used. The recovery of plasmid DNA is on average between 85% and 90%.
Plasmid purity :The JETSTAR-purified plasmid DNA is of higher quality than 2 x CsCl purified plasmid DNA. Corre- spondingly, its recommended application range is extremely wide, including transfection, microinjection, vaccination, gene therapy, fluorescent and radioactive sequencing, amplification, in vitro transcription, cloning, etc.
Culture V olumes and DNA Yields
JETSTAR Kits are preferentially designed to extract and purify high copy plasmid DNA from E.coli cultures. Low copy plasmids can be prepared as well, but larger culture volumes have to be used.
Gentaur recommends LB medium to grow E.coli cells to prepare plasmid DNA with JETSTAR columns. The JETSTAR system is however compatible also with other growth media, especially those designed for enhanced plasmid yields . The cell density should be approximately 1 x 10 cells per ml medium (1-1.5 A 600 units/ml).
High Copy Plasmids (3 - 5 µg DNA/ml LB medium)
A. | Culture Volume | DNA Yield |
Mini | 1 -5 ml | 3 - 20 µg |
Midi | 15 - 25 ml | 45 - 100 µg |
Maxi | 100 ml | 300 - 500 µg |
Low Copy Plasmids (0.2 - 1 µg DNA/ml LB medium)
A. | Culture Volume | DNA Yield |
Mini | 10 - 15 ml | 2 - 45 µg |
Midi | 25 - 100 ml | 5 - 100 µg |
Maxi | 250 - 500 ml | 50 - 500 µg |
Product pricelist:
Product | Contents | Cat.# | Price: |
JETSTAR 2.0 Plasmid Midiprep Kit / 25 | 25 Midi Columns Solutions, Reagents |
2210025 | 126 € |
JETSTAR 2.0 Plasmid Midiprep Kit / 50 | 200 Midi Columns Solutions, Reagents |
210050 | 202 € |
JETSTAR 2.0 Plasmid Midiprep Kit / 250 | 250 Midi Columns Solutions, Reagents |
210250 | 721 € |
JETSTAR 2.0 Plasmid Midiprep LFU Kit / 25 | 50 Midi Columns Solutions, Reagents |
211025 | 186 € |
JETSTAR 2.0 Plasmid Midiprep LFU Kit / 100 | 10 Midi Columns Solutions, Reagents |
211100 | 547 € |
JETSTAR 2.0 Plasmid Maxiprep Kit / 10 | 10 Maxi Columns Solutions, Reagents |
220010 | 126 € |
JETSTAR 2.0 Plasmid Maxiprep Kit / 20 | 20 Maxi Columns Solutions, Reagents |
220020 | 202 € |
JETSTAR 2.0 Plasmid Maxiprep Kit / 100 | 100 Maxi Columns Solutions, Reagents |
220100 | 769 € |
JETSTAR 2.0 Plasmid Maxiprep LFU Kit / 20 | 20 Maxi Columns Solutions, Reagents |
221020 | 289 € |
Super antibodies almost won HIV
In AIDS patients as there is only one hope - to antiretroviral therapy, which is based on drugs that prevent HIV from reproducing. Genome recorded in the virus RNA and thus enter the cell it with reverse transcriptase enzyme (reverse transcriptase) makes a copy of its own DNA template RNA. Then, this DNA was self proteins cells begin RNA viral clone. If, for example, to suppress the work of the reverse transcriptase of the virus, it can not reproduce.
But even cocktails of antiretroviral drugs only help to translate the acute phase of the disease chronic. Such therapy can not do anything with the virus, which floats in the blood or in the cell is dormant. Therefore, researchers are looking for a way to get rid of the virus, rather than just suppressing its ability to reproduce. (By the way, the usual anti-HIV therapy is theoretically allows to get rid of the virus, but only under special conditions, and such cases are, unfortunately, rare.)
HIV and human lymphocyte
When it comes to completely banish HIV, all agree that the best anti tool to be found here. On the one hand, it's simple: just find the immunoglobulins, which would learn viral envelope protein have been associated with him and would have signaled an immune killer cells that this complex must be destroyed. The problem, however, is that HIV has enormous variability, and antibodies usually catch only a certain proportion of the virus particles, for the same protein they endowed with a number of differences that make antibodies do not see it.
However, our immune system is still able to cope with such a variety of the virus , creating a broad-spectrum antibodies . The fact that the immune system can produce immunoglobulins that recognize more than 90 % of the species of HIV , scientists discovered in 2010, and this discovery , of course, has given all hope that AIDS is about to fall . But over time it became clear that such antibodies are rare and a huge amount of time , then only in response to a real infection - that is to provoke a synthesis of a vaccine of killed pathogen will not work.
Nevertheless, scholars have continued to work with the likes of antibodies. And not so long ago have found universal antibodies that appear much earlier and look simpler than those observed before - however, proved their versatility and low. But be sure to make yourself immune to produce such antibodies? The experiments showed the two research groups - Deaconess Medical Center Beth Israel and the National Institute of Allergy and Infectious Diseases (both - USA) - immunoglobulins broad-spectrum, just introduced into the blood, effectively reduce the level of HIV.
HIV between epithelial cells (bottom) and lymphocyte (top)
Immediately it should be said that the group of Dan Baruch (Dan Barouch) and Malcolm Martin (Malcolm Martin) experimented with monkeys: macaques infected with simian-human hybrid HIV, which multiply in monkeys, but looked like a human virus. He served as a weapon against a broad-spectrum antibodies obtained from patients with AIDS.
Dan Baruch and his colleagues used a cocktail of three types of antibodies, and, as the researchers write in Nature, in the week of the virus level down so that it can not be detected! A similar result was also when used instead of a mixture of immunoglobulins only one of their kind. Once the content of such antibodies in the blood began to decline, the concentration of the virus rose again, but some monkeys it was still indistinguishably low even without the introduction of additional portions of antibodies.
In another study carried out by Malcolm Martin and his colleagues, we are talking about the same thing , but here researchers have used different types of antibodies against HIV. Again, the concentration of the virus in macaques fell for seven days prior to the indiscernible ( again: undetectable !) Level and remained so for 56 days, until the antibodies do not begin to fade. Then it all depended on how much virus was originally in monkeys , if small, following the disappearance of virus antibodies remained under the control of its own immunity of animals , and if it was originally much, the level began to rise.
Thus, as emphasized by the researchers, the virus disappeared from both the blood and other tissues, and no resistance to the administered antibodies, it appeared. (However, there was one exception: when the second study administered only one antibody and experimental monkey was a 3-year experience of cohabitation with the virus, it has a sustained viral strain.)
In both cases, scientists are not too long treated the virus with human antibodies because they were afraid that the immune system begins to resent monkeys against foreign immune proteins , and perhaps that was the reason that in most cases, the virus recovered . That is, it is not clear whether it is possible to make the effect of the " long-playing ". All this is clear only after a clinical trial , and as for the results described above , the enthusiasm of researchers can understand the first time in a living organism could so much lower level of viremia (alas , previous experiments with antibodies that were placed on humans and mice had a very unimpressive results ) .
What's next? The cost of antibodies is much higher than the anti-retroviral drugs, and to treat them more difficult. But the authors of the work suggest that such antibodies should be connected to conventional anti-HIV drugs: it will reduce the cost of treatment, and is likely to increase its efficiency - if antibodies to add substances harmful to reproduction of the virus in the cell.
Gene Synthesis
Gene synthesis is the most cost effective way to enhance your research. In as little as 2 weeks, you can have your Gene cloned in hand and 100% sequence guaranteed. And with Gentaur’s great pricing it can cost less to order a synthetic gene from us than to buy all the kits and reagents necessary to PCR, ligate, clone, grow, purify and sequence your gene of interest. If you like, our free codon optimization will increase protein expression rates and can enhance protein function. In addition our optimization can make previously un-clonable sections of DNA easy to work with. Send us your sequence, Gene ID or an accession number. Let us know what you need and we will deliver!
Gentaur also offers mutagenesis as well as cloning and subcloning services. Gentaur strives to provide the highest quality synthetic genes at a great price. Our goal is to always provide you with the best value for your research dollar.
With high throughput DNA synthesis facilities around the world, Gentaur’s daily capacity is unsurpassed. Gentaur is unrivalled in its ability to address the needs of our customers: Whether you need one gene, or one hundred. We respond to your needs–personally.
Features and Benefits
100% Sequence Guarantee: | Individual synthetic genes are confirmed by Sequencing |
Codon Optimization - Free of charge!: | Complimentary codon optimization to enhance protein expression and function |
Value Pricing: | The best value for your research dollar |
Applications
Antibody Construction
Antibodies targeted toward specific diseases or targets can be codon optimized for maximum expression in the host organism. Also, an antibody library can be constructed to screen for the most efficient antibody variant.
Organism Production Optimization
Optimize expression of genes related to resource production to maximize industrial biological production efficiency.
Gene Construction
Get difficult-to-clone DNA sequences easily and enhance the quality of your research by constructing hypothetical genes.
Protein Modification
Codon optimization can increase protein expression efficiency, and a mutant library derived from this process can yield proteins with increased function. Optimizations include secondary structure removal, and repeat reduction as well as organism optimizations.
Schematics of Gene Synthesis Process
Price: 0.25 euro/base
DNA Damage: The Dark Side of Respiration
Adventitious changes in cellular DNA can endanger the whole organism, as they may lead to life-threatening illnesses like cancer. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts of respiration cause mispairing of subunits in the double helix.
The DNA in our cells controls the form and function of every cell type in our bodies. The instructions for this are encoded in the linear sequence of the four subunits found in DNA, the bases adenine (A), cytosine (C), guanine (G) and thymine (T). Random changes in the sequence can lead to cell dysfunction, and may result in unrestricted cell proliferation and malignancies. Mutations can be induced by a variety of agents. For example, cellular respiration, i.e. the reduction of inspired oxygen to water, which powers cell function, also generates highly reactive oxygen species that can damage DNA, with the purine bases G and A being particularly susceptible to this kind of attack.
"Reactive oxygen species are responsible for two different sorts of DNA damage, as they induce formation of both 8-oxo-G and FaPy-G," says Professor Thomas Carell of the Department of Chemistry at LMU. In 2004, work done by Carell and his team defined how 8-oxo-G generates mutations. However, the basis for the mutagenic effect of FaPy-G has remained obscure -- until now. In their latest publication, Carell and his colleagues describe how FaPY-G leads to mispairing of bases in the double helix.
Pernicious partner swapping One G in one strand of the double helix normally matches up with a C on the other, forming a G:C pair. But as a consequence of damage by reactive oxygen species, the guanine base may be transformed into FaPy-G, so that we get a FaPy-G:C base pair. "We have now shown that, in the course of DNA replication prior to cell division, FaPy-G interacts with adenine, leading to the formation of FaPy-G:A base pairs. This partner swap is unusual, since unmodified guanine normally does not team up with adenine," Carell notes.
FaPy-G is subsequently recognized as abnormal and is removed by DNA repair enzymes. The missing base is replaced by a T -- which is the usual partner for A. The net result is that the original G:C base pair has been converted into an A:T pair, and the base sequence has undergone a potentially dangerous mutation.
This outcome is made possible by the fact that the cell's damage-control systems find it surprisingly difficult to distinguish the normal guanine base from its aberrant derivative FaPy-G during DNA replication. "That this defect then leads to mispairing with adenine is one of the main reasons for the spontaneous development of tumors," says Carell. "So with every breath we take, our risk of getting cancer goes up by a teeny-weeny bit." Further insights into the reasons why FaPy-G often eludes the cell's detection and correction systems could help to improve the treatment of cancer, as the inhibition of DNA repair processes in tumor cells increases their sensitivity to chemotherapeutic drugs.
The study was supported by DFG grants awarded to Collaborative Research Centers 646 and 749 and the Center for Integrated Protein Science Munich (CIPSM), an Excellence Cluster.